Summary
Corona Remedies Share Price: Corona Remedies’ initial public offering sought to raise Rs 655.68 crore through the sale of 0.62 million shares by promoters Dr Kirtikumar Mehta, Laxmidas Mehta, Minaxi Kirtikumar Mehta, Dipabahen Niravkumar Mehta, Bhrinda Ankur Mehta, along with existing investors Anchor Partners, Sepia Investments, and Sage Investment Trust.
Corona Remedies shares prices: Corona Remedies, a pharmaceutical company, made an impressive debut on Monday, 15 December, when its shares first started trading publicly.
Corona Remedies’ debut at the stock exchange was notable due to a significant premium over its initial issue price, yielding substantial gains for investors. This pharmaceutical company specializes in women’s healthcare, pain management, cardio-diabetes treatment, and its shares were officially listed on Monday, 15 December 2018.
The stock opened trading at Rs1,470 a share on the National Stock Exchange, representing a premium of 38.42% over its IPO price of Rs1,062. Likewise, on the Bombay Stock Exchange, it gained 36.72% – reflecting both strong market performance and enthusiastic investor participation. Corona Remedies share price.
Corona Remedies’ Initial Public Offering (IPO) consisted of an Offer for Sales (OFS) of 0.6 million shares, conducted jointly by Anchor Partners, Sepia Investments and Sage Investment Trust, as well as promoters Dr. Kirtikumar, Laxmidas Minaxi Kirtikumar, and Dipabahen Bhrinda, with each lot containing 14 shares offering investors an average listing profit of Rs20.580 per lot.
The IPO was met with overwhelming investor enthusiasm, as it was subscribed 137.04 times. Institutional buyers–Qualified Institute Buyers (QIBs), saw subscription rates reach 288.52 times while non-institutional investors saw subscription levels hit 208.88 times; retail investors also responded well and subscribed 28.73 times; SBI Mutual Funds, ICICI Prudential Mutual Funds HDFC Mutual Funds Axis Mutual Funds as well as SBI Life Insurance were prominent anchor investors who participated in pre IPO placement arrangements as part of an aggressive pre IPO placement, totalling Rs195 Crores; these investors included SBI Mutual Funds SBI Mutual Funds as well as significant pre IPO placement by prominent anchor investors such as SBI Mutual Funds SBI Mutual Funds as well as SBI Life Insurance among others.
Corona Remedies is confident that its equity listing will boost brand visibility, improve liquidity and further solidify its position in India’s expanding healthcare market. Investors have expressed great enthusiasm about its performance so far.
Create whatever you please! You have limitless possibilities.
- The National Stock Exchange listed the stock at Rs 1,470 per share, an increase of 38.42% over its IPO price of Rs 1,062.
- The stock began trading at Rs 1,452, an increase of 36.72 percent from its issue price.
Image
Corona Remedies Share Price: How Did Investors Fare Per Lot, Corona Remedies share price
Corona Remedies share price’ Initial Public Offering (IPO) yielded investors who purchased lots with 14 shares each an investment return of Rs 20,580 per lot.
The initial public offering aimed to raise Rs655.68 billion through an offer for sale (OFS) of 0.62 million shares by Dr Kirtikumar Mehta, Laxmidas Mehta, Minaxi Kirtikumar Mehta, Dipabahen Mehta, Bhrinda Ankur Mehta, as well as existing investors Anchor Partners, Sepia Investments, and Sage Investment Trust.
Nephrocare Health Services Initial Public Offering Allotment Status Check Online on NSE BSE KFin Technologies; Listing Date and Time available here.
“Our Company believes that listing equity shares will strengthen its brand, visibility and liquidity for shareholders while simultaneously creating an equity share market in India,” according to its prospectus.
According to BSE data, the IPO generated an investment bid totaling USD137.04 as investors bid for 62.65.41.440 equity shares versus 45.71.882 offered for sale.
| Category | Reserved | No of Shares Bid For | No of Times |
| Qualified Institutional Buyers | 12,88,732 | 35,89,39,448 | 278.52 |
| Non-Institutional Investors | 9,66,549 | 20,18,97,066 | 208.88 |
| Retail Investors | 22,55,281 | 6,48,02,038 | 28.73 |
| Total | 45,71,882 | 62,65,41,440 | 137.04 |
Prior to its IPO, the company raised Rs195 crore from anchor investors such as SBI Mutual Fund, ICICI Prudential Mutual Fund (MF), HDFC Mutual Funds, Axis Mutual Funds, Invesco MF DSP Kotak Mutual Fund and SBI Life Insurance Company. Corona Remedies is a pharmaceutical company located in Ahmedabad that specialises in women’s health, pain management, cardio-diabetes, urology and other therapeutic fields. Corona Remedies share price if you want digital marketing service click here
